Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;90(6):1112-1114.
doi: 10.1038/s41390-021-01384-y. Epub 2021 Feb 18.

Ensuring continued progress for development of COVID-19 therapeutics in children

Gary J Noel  1 , Roberta L DeBiasi  2 , Wallace Crandall  3 , Edward M Connor  4
Affiliations

Ensuring continued progress for development of COVID-19 therapeutics in children

Gary J Noel et al. Pediatr Res. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors delcare no competing interests.

Figures

Fig. 1
Fig. 1. Pediatric development of new therapies considers the continuum of disease condition/response between adults and children.
Extrapolating the experience in adults to children varies depending on the similarity and differences in the condition and response to therapy for that condition. For direct antiviral agents, establishing therapeutic benefit may proceed in alignment with COVID-19 condition/response being similar or the same between adults and children. Establishing therapeutic benefit for other therapies, such as host defense modulators, will require considering the similarity and differences in condition/response between adults and children in planning for the work needed to establish therapeutic benefit for children.
See this image and copyright information in PMC

References

    1. DeBiasi, R. L. et al. Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. J. Pediatr.10.1016/j.jpeds.2020.05.007 (2020). - PMC - PubMed
    1. Zachariah, P. et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a Children’s Hospital in New York City, New York. JAMA Pediatr. e202430. 10.1001/jamapediatrics.2020.2430 (2020). - PMC - PubMed
    1. Beigel JH, et al. Remdesivir for the treatment of Covid-19—preliminary report. N. Engl. J. Med. 2020;383:992–994. doi: 10.1056/NEJMoa2007764. - DOI - PubMed
    1. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Nat. Rev. 2020;19:149–150. - PubMed
    1. Zhong, J., Tamg, J., Ye, C. & Dong, L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol.10.1016/S2665-9913(20)30120-X (2020). - PMC - PubMed

Substances

LinkOut - more resources